Valuation Metrics Reflect Improved Price Attractiveness
As of 2 June 2026, Windlas Biotech’s price-to-earnings (P/E) ratio stands at 25.29, a figure that marks a significant improvement in valuation attractiveness compared to its previous standing. This P/E ratio is considerably lower than several of its industry peers, including Gland Pharma (36.11), Ajanta Pharma (34.73), and Wockhardt, which trades at a very expensive P/E of 116.55. The company’s price-to-book value (P/BV) ratio of 2.89 further supports this valuation shift, positioning Windlas Biotech as more reasonably priced relative to its net asset base.
Other valuation multiples such as EV to EBIT (19.53) and EV to EBITDA (13.80) also indicate a more balanced price point, especially when contrasted with the elevated multiples seen in competitors like Sai Life Sciences (EV/EBITDA of 38.72) and Neuland Laboratories (38.16). This relative moderation in valuation multiples suggests that Windlas Biotech is trading at a discount to many of its sector counterparts, potentially offering investors a more attractive entry point.
Financial Performance and Returns Contextualise Valuation
Windlas Biotech’s return on capital employed (ROCE) of 21.40% and return on equity (ROE) of 11.44% reflect solid operational efficiency and shareholder returns, underpinning the valuation improvements. The company’s dividend yield remains modest at 0.72%, consistent with its growth-oriented profile.
Examining stock performance relative to the broader market, Windlas Biotech has outperformed the Sensex over multiple time horizons. Year-to-date, the stock has delivered a 2.43% return compared to the Sensex’s decline of 12.85%. Over three years, the stock’s cumulative return of 200.33% vastly exceeds the Sensex’s 18.96%, highlighting strong long-term growth momentum despite recent volatility. However, the one-year return of -11.62% indicates some near-term pressure, reflecting sector-wide challenges and stock-specific factors.
Mojo Grade Downgrade and Market Capitalisation Considerations
Despite the improved valuation grade from fair to attractive, MarketsMOJO downgraded Windlas Biotech’s overall Mojo Grade from Hold to Sell on 4 February 2026, assigning a score of 42.0. This downgrade reflects concerns beyond valuation, possibly linked to earnings quality, market risks, or competitive pressures. The company remains classified as a small-cap, which inherently carries higher volatility and liquidity considerations compared to large-cap peers.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
Comparative Valuation: Windlas Biotech Versus Peers
When benchmarked against its Pharmaceuticals & Biotechnology peers, Windlas Biotech’s valuation multiples stand out for their relative moderation. For instance, Gland Pharma, a key competitor, trades at a P/E of 36.11 and EV/EBITDA of 21.27, both substantially higher than Windlas’s 25.29 and 13.80 respectively. Similarly, Ajanta Pharma’s P/E of 34.73 and EV/EBITDA of 26.00 underscore a pricier market perception.
More expensive peers such as J B Chemicals & Pharmaceuticals and Wockhardt, with P/E ratios of 46.79 and 116.55 respectively, highlight the premium investors place on established market leaders or those with stronger earnings visibility. Windlas Biotech’s PEG ratio of 2.45, while higher than some peers like Gland Pharma (0.73) and Wockhardt (0.16), reflects expectations of moderate earnings growth relative to price, suggesting cautious optimism among investors.
Stock Price Movement and Volatility
On 2 June 2026, Windlas Biotech’s stock closed at ₹814.35, down 2.14% from the previous close of ₹832.20. The day’s trading range was ₹810.50 to ₹848.90, indicating intraday volatility. The stock remains well below its 52-week high of ₹1,095.00 but comfortably above the 52-week low of ₹699.35, signalling a recovery phase after recent corrections.
Such price dynamics, combined with the improved valuation grade, suggest that the market is recalibrating expectations for Windlas Biotech, potentially factoring in both near-term risks and longer-term growth prospects.
Considering Windlas Biotech Ltd? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this small-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Investment Implications and Outlook
Windlas Biotech’s transition to an attractive valuation grade amidst a Sell Mojo Grade rating presents a complex investment scenario. The improved P/E and P/BV ratios relative to peers and historical levels suggest that the stock is priced to reflect a discount, potentially offering value for investors willing to navigate small-cap volatility and sector-specific risks.
However, the downgrade in overall Mojo Grade to Sell signals caution, likely reflecting concerns over earnings consistency, competitive pressures, or broader market headwinds impacting the Pharmaceuticals & Biotechnology sector. Investors should weigh these factors carefully, considering Windlas Biotech’s strong long-term returns against recent underperformance and valuation risks.
Given the company’s robust ROCE of 21.40% and reasonable ROE of 11.44%, operational fundamentals remain sound. The modest dividend yield of 0.72% aligns with a growth-focused strategy, which may appeal to investors prioritising capital appreciation over income.
In summary, Windlas Biotech’s valuation parameters have improved significantly, making the stock more price-attractive compared to many peers. Yet, the overall negative Mojo Grade and recent price volatility suggest that investors should approach with measured caution, ideally as part of a diversified portfolio strategy within the Pharmaceuticals & Biotechnology sector.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
